Novaliq dissolvable drops improve eye quality in clinical trials

Drug delivery company Novaliq GmbH today announced that its clinical stage NovaTears OTC eye drops were effective in patients with mild to moderate evaporative dry eye disease.

The German company said tear film fluid and stability improved during the 5- to 7-week study period. In addition, there was less corneal damage after treatment, according to the release.

The product has had a CE mark since July 2013. Now the company is seeking to enter the market in various regions, according to a news release. 

Novaliq's semifluorinated alkanes (SFA) drug delivery system is an alternative medium to water, the company says. The SFAs dissolve compounds, enabling them to penetrate the eye's barriers and reach their target. They also improve the stability of drugs by preventing water from cleaving chemical bonds, according to the website. 

All 6 of the company's clinical-stage products are for eye indications, but the company website says the technology could also be used to extend the viability of organs for transplantation.

- read the release
- more on the delivery platform 

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.